Subjects will be treat ed for up to 2 years (up to 1 year in each treatment phase) or until they experience progressive disease, unacceptable toxicity (not corrected with dose reduction), withdraw consent , or if the Investigator feels it is no longer in their best interest to continue treatment. NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 5 Confidential and Proprietary 13 Duration of Follow -up: Subjects who discontinue study treatment should remain in the study and continue to be followed for: • CT or MRI scan assessment (see Section 6.1.2 ) • Collection of vital status every 90 days (± 14 days) Subjects should be followed until either death (any cause) or for a minimum of 24 months past administration of the first dose of study drug. Following documented PD, subjects may continue to be followed by the investigational physician or a third party by phone or review of medical records until withdrawal of consent, lost to follow -up, or death (by any cause). Additional information from a subject’s medical records relevant to this study may be provided to NantKwest as needed to understand the safety and efficacy of the regimen tested in this protocol. Reference Therapy, Dosage, and Mode of Administration: Not applicable. Evaluation of Endpoints: Safety: Safety endpoints include assessments of treatment -emergent AEs, SAEs, and clinically significant changes in safety laboratory tests, physical examinations, electrocardiograms (ECGs), echocardiograms (ECHOs), and vital signs. All subjects will be evaluable for toxicity from the time of their first study treatment.